Eylea Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Aflibercept

Indications/Uses

Neovascular (wet) age-related macular degeneration (nAMD); visual impairment due to diabetic macular oedema (DME) in adults.

Dosage/Direction for Use

Intravitreal inj nAMD & DME 8 mg (equiv to 0.07 mL). Initiate w/ 1 inj mthly for 3 consecutive doses. May be extended up to every 4 mth. May be further extended up to 5 mth (eg, treat-&-extend dosing regimen) while maintaining stable visual &/or anatomic outcomes.

Contraindications

Hypersensitivity. Ocular or periocular infection. Active severe intraocular inflammation.

MIMS Class

Other Eye Preparations

ATC Classification

S01LA05 - aflibercept ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.

Regulatory Classification

POM

Presentation/Packing

Form

Eylea soln for inj 114.3 mg/mL

Packing/Price

1's

Eylea

aflibercept

Manufacturer:

Catalent Indiana, LLC